167 related articles for article (PubMed ID: 21728814)
1. Diagnostic testing for vaccinomics: is the regulatory approval framework adequate? A comparison of Canada, the United States, and Europe.
Joly Y; Koutrikas G; Ramos-Paque E; Zawati M; Gardy J; Hayden MR; Carleton BC
OMICS; 2011 Sep; 15(9):597-605. PubMed ID: 21728814
[TBL] [Abstract][Full Text] [Related]
2. Steering vaccinomics innovations with anticipatory governance and participatory foresight.
Ozdemir V; Faraj SA; Knoppers BM
OMICS; 2011 Sep; 15(9):637-46. PubMed ID: 21848419
[TBL] [Abstract][Full Text] [Related]
3. Designing the next generation of vaccines for global public health.
Bagnoli F; Baudner B; Mishra RP; Bartolini E; Fiaschi L; Mariotti P; Nardi-Dei V; Boucher P; Rappuoli R
OMICS; 2011 Sep; 15(9):545-66. PubMed ID: 21682594
[TBL] [Abstract][Full Text] [Related]
4. Regulatory approval for new pharmacogenomic tests: a comparative overview.
Joly Y; Koutrikas G; Tassé AM; Issa A; Carleton B; Hayden M; Rieder MJ; Ramos-Paque E; Avard D
Food Drug Law J; 2011; 66(1):1-24, i. PubMed ID: 24505844
[TBL] [Abstract][Full Text] [Related]
5. Twenty-first century vaccinomics innovation systems: capacity building in the global South and the role of Product Development Partnerships (PDPs).
Huzair F; Borda-Rodriguez A; Upton M
OMICS; 2011 Sep; 15(9):539-43. PubMed ID: 21732822
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic kits in parasitology: which controls?].
Rossi P
Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics.
Poland GA; Ovsyannikova IG; Jacobson RM; Smith DI
Clin Pharmacol Ther; 2007 Dec; 82(6):653-64. PubMed ID: 17971814
[TBL] [Abstract][Full Text] [Related]
8. Incidental findings in data-intensive postgenomics science and legal liability of clinician-researchers: ready for vaccinomics?
Zawati MH; Hendy M; Joly Y
OMICS; 2011 Sep; 15(9):615-24. PubMed ID: 21728813
[TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
11. Publics and vaccinomics: beyond public understanding of science.
Einsiedel EF
OMICS; 2011 Sep; 15(9):607-14. PubMed ID: 21732820
[TBL] [Abstract][Full Text] [Related]
12. Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
Breman JG; Alilio MS; Mills A
Am J Trop Med Hyg; 2004 Aug; 71(2 Suppl):1-15. PubMed ID: 15331814
[TBL] [Abstract][Full Text] [Related]
13. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
14. Regulation of vaccines: strengthening the science base.
Milstien JB
J Public Health Policy; 2004; 25(2):173-89; discussion 190-6. PubMed ID: 15255384
[TBL] [Abstract][Full Text] [Related]
15. The development of West Nile virus safety policies by Canadian blood services: guiding principles and a comparison between Canada and the United States.
Vamvakas EC; Kleinman S; Hume H; Sher GD
Transfus Med Rev; 2006 Apr; 20(2):97-109. PubMed ID: 16565024
[TBL] [Abstract][Full Text] [Related]
16. Tobacco and cancer: an American Association for Cancer Research policy statement.
Viswanath K; Herbst RS; Land SR; Leischow SJ; Shields PG;
Cancer Res; 2010 May; 70(9):3419-30. PubMed ID: 20388799
[TBL] [Abstract][Full Text] [Related]
17. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
[TBL] [Abstract][Full Text] [Related]
18. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
19. Impact of regulatory science on global public health.
Patel M; Miller MA
Kaohsiung J Med Sci; 2012 Jul; 28(7 Suppl):S5-9. PubMed ID: 22871603
[TBL] [Abstract][Full Text] [Related]
20. Theranostics in primary care: pharmacogenomics tests and beyond.
Bartlett G; Antoun J; Zgheib NK
Expert Rev Mol Diagn; 2012 Nov; 12(8):841-55. PubMed ID: 23249202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
